submit urlsubmit rss feedadd directoryphysician directoryPharmacology employment

article

Basic Information (Chemical, Pharmacological, Marketing Data)


Eptifibatide (Integrilin®, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. It reversibly binds to platelets and has a short half-life. Eptifibatide is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody Abciximab and the non-peptid Tirofiban entered the global market. The Eptifibatide molecule constitutes a cyclic heptapeptide and belongs to the class of the so called arginin-glycin-aspartat-mimetics.

The drug is sold in two strengthes : vials containing 2mg/ml (20mg totally) and 0.75mg/ml (75mg totally).

More on [ Eptifibatide ]


directory of related categories

 
Eptifibatide RSS feed
Eptifibatide - Twitter Search

Safety of Eptifibatide for Subcortical Stroke Progression http://twurl.nl/7vt30k
Gron_neurologen (Groninger Neurologen) Thu, 15 Oct 2009 22:12:17 -0000
Safety of Eptifibatide for Subcortical Stroke Progression http://twurl.nl/7vt30k

 
Subscribe to Eptifibatide RSS feed

directory of related sites

Integrilin Consumer Information - FDA - Patient FAQ in html format with a link to approved labeling in pdf format.

Eptifibatide related videos

 

HOMEADVERTISINGABOUT US

articlesartsbusinesscomputersgameshealthhospitalshomekids & teensnewsmobilephysiciansrecreationreferenceregionalscienceshoppingsocietysportsworld


Submit a Site About Become an Editor